Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 23.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,884,730 shares of the company’s stock after buying an additional 735,160 shares during the quarter. JPMorgan Chase & Co.’s holdings in Apellis Pharmaceuticals were worth $112,036,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of APLS. Exome Asset Management LLC boosted its holdings in Apellis Pharmaceuticals by 114.0% in the third quarter. Exome Asset Management LLC now owns 100,367 shares of the company’s stock valued at $2,895,000 after purchasing an additional 53,467 shares during the period. Virtu Financial LLC purchased a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $390,000. Old West Investment Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the third quarter worth about $2,953,000. Toronto Dominion Bank increased its stake in shares of Apellis Pharmaceuticals by 4.2% during the third quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock worth $739,000 after buying an additional 1,022 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Apellis Pharmaceuticals by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock valued at $52,229,000 after acquiring an additional 22,609 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Up 0.0 %

Apellis Pharmaceuticals stock opened at $31.91 on Thursday. The stock has a 50 day moving average of $31.12 and a two-hundred day moving average of $34.03. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $73.80. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of -15.72 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was up 78.3% on a year-over-year basis. During the same quarter last year, the business earned ($1.17) earnings per share. As a group, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Analysts Set New Price Targets

APLS has been the topic of a number of recent analyst reports. Mizuho dropped their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target on the stock. in a research note on Tuesday, December 17th. William Blair assumed coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating for the company. JPMorgan Chase & Co. cut their target price on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research report on Friday, September 13th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $25.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).